Bioequivalence of Lamotrigine 50-mg Tablets in Healthy Male Volunteers: a Randomized, Single-Dose, 2-Period, 2-Sequence Crossover Study

Abstract

Objective:

To compare the bioavailability of two 50-mg lamotrigine dispersible tablet formulations (Epilepax^®, Ivax-TEVA Argentina Laboratories, Argentina, as a test formulation, and Lamictal^®, GlaxoSmithKline, UK, as a reference formulation) in 24 healthy male volunteers.

Material and Methods:

This study was a randomized, 2-period, 2-sequence crossover design that was open for subjects and investigators, but blind for the bioanalytical lab. Serum samples were obtained over a 120-h interval. A 9-day wash-out period was allowed between treatments. The concentrations of lamotrigine were analyzed by high-performance liquid chromatography followed by ultraviolet-visible detection. Lamotrigine time-concentrations curves were obtained and the following pharmacokinetic parameters were calculated: AUC_0–t, AUC_0–inf and Cmax. Bioequivalence was declared if the 90% confidence interval (CI) of the mean test/reference ratios for AUC_0–t, AUC_0–inf and Cmax were within 80.00–125.00%.

Results:

The geometric mean and respective 90% CI of test/reference percent ratios were 100.83% (92.53–107.88%) for AUC_0–t, 99.91% (93.79–108.40%) for AUC_0–inf, and 95.62% (90.91–100.57%) for Cmax. No serious adverse events were observed. 1 patient reported a mild rash following the administration of each formulation.

Conclusion:

This single dose study found that the test and reference products met the regulatory criteria for bioequivalence in this sample of fasting healthy volunteers. These results suggest that bioequivalence studies evaluating 50-mg doses of Lamotrigine are feasible and recommended, since such doses may minimize the risk of severe rash or Stevens-Johnson Syndrome. This study was registered at the Argentinean Clinical Trials National Registry (www.anmat.gov.ar), No 1666/2008.

Key words

lamotrigine - safety - pharmacokinetics - bioequivalence - epilepsy - bioavailability

• References

• 1 Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005; 46 (Suppl. 09) 140-148
• 2 Lees G, Leach MJ. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 1993; 612: 190-199
• 3 Hitiris N, Brodie MJ. Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs. Epilepsia 2005; 46 (Suppl. 09) 149-153
• 4 Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav 2009; 15: 56-65
• 5 Weisler RH, Calabrese JR, Bowden CL et al. Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. J Affect Disord 2008; 108: 1-9
• 6 Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2006; 2: 1009-1018
• 7 Cohen AF, Land GS, Breimer DD et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535-541
• 8 Eriksson AS, Hoppu K, Nergardh A et al. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996; 37: 769-773
• 9 Sinz MW, Remmel RP. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos 1991; 19: 149-153
• 10 Bowden CL, Asnis GM, Ginsberg LD et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173-184
• 11 Biton V, Mirza W, Montouris G et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-177
• 12 Morrell MJ, Isojarvi J, Taylor AE et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003; 54: 189-199
• 13 Aldenkamp AP, Baker G. A Systematic Review of the Effects of Lamotrigine on Cognitive Function and Quality of Life. Epilepsy Behav 2001; 2: 85-91
• 14 Edwards KR, Sackellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double-Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28-36
• 15 Guberman AH, Besag FM, Brodie MJ et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985-991
• 16 Messenheimer J, Mullens EL, Giorgi L et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998; 18: 281-296
• 17 Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998; 25: S14-S18
• 18 Guidance for Industry: Bioanalytical Method Validation [Internet]. Food and Drug Administration Center for Drug Evaluation and Research. 2001 May. [Cited: 2011 Aug 1]. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
• 19 Guideline on the investigation of bioequivalence. [Internet]. European Medicines Agency Committe for Medicinal Products for Human Use. 2010 Aug. [Cited: 2011 Aug 1]. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
• 20 Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products [Internet]. Food and Drug Administration Center for Drug Evaluation and Research; 2003 Mar [Cited: 2011 Aug 1]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf
• 21 GlaxoSmithKline. LAMICTAL prescribing information. [Internet]. 2005. [Cited: 2011 Aug 1]. Available from: http://us.gsk.com/products/assets/us_lamictal.pdf
• 22 Aldenkamp AP, Arends J, Bootsma HP et al. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002; 43: 19-26
• 23 Colucci R, Glue P, Holt B et al. Effect of felbamate on the pharmacokinetics of lamotrigine. J Clin Pharmacol 1996; 36: 634-638
• 24 Depot M, Powell JR, Messenheimer Jr JA et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990; 48: 346-355
• 25 Ebert U, Thong NQ, Oertel R et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000; 56: 299-304
• 26 Hermann R, Knebel NG, Niebch G et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003; 58: 795-802
• 27 Li X, Teneback CC, Nahas Z et al. Interleaved transcranial magnetic stimulation/functional MRI confirms that lamotrigine inhibits cortical excitability in healthy young men. Neuropsychopharmacology 2004; 29: 1395-1407
• 28 Makatsori A, Duncko R, Moncek F et al. Modulation of neuroendocrine response and non-verbal behavior during psychosocial stress in healthy volunteers by the glutamate release-inhibiting drug lamotrigine. Neuroendocrinology 2004; 79: 34-42
• 29 Shiah IS, Yatham LN, Lam RW et al. Effects of lamotrigine on the 5-HT1A receptor function in healthy human males. J Affect Disord 1998; 49: 157-162
• 30 Srichaiya A, Longchoopol C, Oo-Puthinan S et al. Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study. Clin Ther 2008; 30: 1844-1851
• 31 Webb J, Kamali F. Analgesic effects of lamotrigine and phenytoin on cold-induced pain: a crossover placebo-controlled study in healthy volunteers. Pain 1998; 76: 357-363
• 32 Makus KG, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007; 29: 334-341
• 33 Draft Guidance on Lamotrigine [Internet]. Food and Drug Administration Center for Drug Evaluation and Research. 2010 Jul [Cited: 2011 Aug 1]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209231.pdf